Because excessive activation of C3-derived molecules and their associating molecules is causal for several renal diseases, their inhibitors, such as a C3-targeting peptide and a factor B-blocking compound, have been developed and are currently under clinical evaluation (66). This evidence concerns the gene C3 and kidney disorder.